A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Clinical trial NCT06707610 · RECRUITING
Trial details
- NCT number
- NCT06707610
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-10
- Primary completion
- 2027-12-01
- Enrollment
- 234
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.